Researchers at Johns Hopkins develop a novel therapy, JHU083, to reprogram immune cells in treating resistant prostate and bladder cancers, with plans for clinical trials.
Researchers at Johns Hopkins Kimmel Cancer Center developed a novel therapy, JHU083, that reprograms immune cells to suppress growth of hard-to-treat prostate and bladder cancers in mice. The glutamine-blocking drug inhibits cancer cell growth, induces tumor cell death, and reprograms immune-suppressing macrophages into immune-enhancing macrophages. Johns Hopkins plans to conduct a clinical trial to evaluate JHU083's effectiveness in shrinking tumors and preventing metastasis in patients with treatment-resistant prostate or bladder cancer.
May 21, 2024
3 Articles